Quick answer
On 21 September 2026, Beijing Anzhen Hospital (Capital Medical University) was one of five leading Chinese structural-heart centres to complete the country's first clinical implants of Abbott's TriClip TEER G4 — a transcatheter edge-to-edge repair (TEER) system built specifically for the tricuspid valve. The device offers a minimally invasive option for severe tricuspid regurgitation, especially in older or surgical high-risk patients who cannot tolerate open-heart surgery [1][2].
Key takeaways
- China's first batch of TriClip TEER G4 implants was completed simultaneously on 21 September 2026 at five top centres, including Anzhen, Zhongshan, West China, the Second Affiliated Hospital of Zhejiang University, and Fuwai [2].
- TriClip is the first transcatheter tricuspid repair device approved in China built specifically for tricuspid anatomy and validated by large randomised trials (the TRILUMINATE pivotal trial) [1][4].
- Tricuspid regurgitation affects an estimated 8–10 million people in China and rises steeply with age, reaching nearly 4% in people over 75 [1].
- Untreated severe tricuspid regurgitation carries a 5-year survival of only 60–70%, while open surgery has an in-hospital mortality of 8–10%, leaving many patients with no good option [3].
- Reported outcomes were favourable: smooth procedural flow, stable device performance, good immediate results and recovery [2].
The procedure and the device
The tricuspid valve is the one-way gate between the right atrium and right ventricle. When it fails to close properly, blood flows backwards — tricuspid regurgitation — which overloads the right heart and can progress to right-heart failure. TriClip TEER G4 repairs the valve from inside the heart by clipping the leaflets together through a catheter, without opening the chest. Its design addresses the tricuspid valve's tricky anatomy, where many patients have more than three leaflets and wide coaptation gaps that made earlier mitral-focused devices hard to use [3].
What was reported
At the five centres, the procedures ran smoothly with stable device performance and immediate post-procedure benefit. The launch marks China's entry into dedicated transcatheter tricuspid therapy, a field that lagged behind aortic and mitral interventions for two decades because of the valve's anatomical difficulty [1][2].
About 40% of patients have more than three tricuspid leaflets, with thin leaflets, wide gaps and a short septal leaflet — far harder to clip than the mitral valve. Drug therapy only relieves symptoms and cannot stop the leak, and surgery is too risky for many older patients. That gap is what a dedicated TEER device is designed to close [3].
The condition in context: tricuspid regurgitation
Tricuspid regurgitation is common, under-recognised and often tolerated until it becomes severe. Symptoms such as abdominal bloating, poor appetite and leg swelling are easily mistaken for indigestion or ageing, so many patients present late [1].
| Region | What the data shows | Source |
|---|---|---|
| China | An estimated 8–10 million people have tricuspid regurgitation; prevalence is about 4% in those over 75 [1]. | Guangming Health report [1] |
| Severe disease | Untreated severe tricuspid regurgitation has a 5-year survival of 60–70%; open-heart surgery carries 8–10% in-hospital mortality [3]. | Device review (medical trade press) [3] |
| Worldwide | Tricuspid regurgitation is frequent and long under-treated, with few dedicated therapies until recent transcatheter options [5]. | StatPearls (NCBI) [5] |
Because medical therapy cannot halt the leak and surgery excludes many frail patients, a minimally invasive, anatomy-specific repair addresses a real unmet need [1][3].
Why it matters
| For the patient | What the report suggests | Source |
|---|---|---|
| Access | A dedicated tricuspid TEER device, now in China, expands minimally invasive options for severe disease [1][2]. | [1][2] |
| Evidence | The device is backed by a large randomised trial (TRILUMINATE), not just single cases [4]. | [4] |
| Caution | Initial rollout data are early and selected; long-term outcomes in Chinese patients will follow [2]. | [2] |
Availability and limits
- This is an editorial summary of press and trade reports, not an independent clinical assessment or a booking channel [1][2][3].
- The first-batch reports describe successful immediate outcomes; long-term follow-up and peer-reviewed Chinese data are pending [2].
- TriClip is approved in China (registration numbers cited in reports), but the number of centres and reimbursement vary [1][2].
- Burden figures come from a press report and a reference text, not from the procedure series [1][5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Do I have severe tricuspid regurgitation, and am I a candidate for TEER? | Candidacy depends on valve anatomy, right-heart function and surgical risk; requires on-site imaging [1][3]. |
| Which department handles foreign patients, and in what language? | Anzhen is a working hospital we do not book; confirm international-department coordination and language support. |
| Is TriClip available here now, and at what cost? | The device just launched; confirm current availability, reimbursement and pricing [1][2]. |
| What follow-up and imaging will I need? | Transcatheter repair requires structured follow-up; plan travel and visits accordingly. |
Questions patients ask
What is TriClip TEER G4?
It is Abbott's transcatheter edge-to-edge repair system built specifically for the tricuspid valve. It clips the valve leaflets together through a catheter, repairing the leak without open-heart surgery, and is the first such tricuspid-specific device approved in China, supported by the TRILUMINATE randomised trial [1][4].
Did Anzhen really do China's first TriClip procedure?
Anzhen was one of five leading centres that completed China's first batch of TriClip TEER G4 implants simultaneously on 21 September 2026, alongside Zhongshan, West China, the Second Affiliated Hospital of Zhejiang University, and Fuwai [2].
Why does tricuspid regurgitation need a special device?
The tricuspid valve is anatomically difficult — many patients have more than three thin leaflets and wide gaps — which made mitral-focused devices harder to use. TriClip was designed for this anatomy [3].
How serious is severe tricuspid regurgitation?
Untreated severe tricuspid regurgitation has a 5-year survival of 60–70%, and open surgery carries 8–10% in-hospital mortality, leaving many older patients with few options [3].
Is this relevant to international patients considering heart care in China?
It is useful context for structural-heart care in China, which is adopting tricuspid TEER. Anzhen is a working hospital we do not book — contact its international department directly and confirm candidacy, language support and travel logistics before committing [1][2].